<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1781">
  <stage>Registered</stage>
  <submitdate>17/12/2007</submitdate>
  <approvaldate>17/12/2007</approvaldate>
  <nctid>NCT00576277</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain</studytitle>
    <scientifictitle>A Prospective, Double-Blind, Randomized, Placebo-Controlled Trial of AV411 to Assess Its Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in the Treatment of Neuropathic Pain</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AV411-010</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetic Neuropathy</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AV411

Treatment: drugs: AV411


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Tolerability</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetic profile</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacodynamic profile</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Brief Pain Inventory</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Visual Analog Scale</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Global Impression of Change</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Use of analgesic or adjuvant medications for neuropathic pain</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation between plasma concentrations of AV411 and pain intensity assessments</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of diabetic neuropathy or complex regional pain syndrome of at least 6
             months duration

          -  VAS score of 4 cm or higher at Screening

          -  No clinical abnormality in laboratory and urine analyses

          -  Electrocardiogram within normal limits at Screening

          -  Negative pregnancy test on Study Day 1 for female subjects of childbearing potential

          -  On stable doses of medications, analgesic or others for at least 8 weeks prior to
             study enrollment

          -  Willing to use barrier contraceptive during the period of the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known hypersensitivity to AV411 or its components

          -  Conditions which might affect drug absorption, metabolism or excretion

          -  Untreated mental illness, current drug addiction or abuse or alcoholism

          -  Donated blood in the past 90 days or have poor peripheral venous access

          -  Platelets &lt;100,000mm3 or a history of thrombocytopenia

          -  Known or suspected chronic liver disease

          -  GFR &lt;=90mL/min/1.73m2 (Cockcroft-Gault)

          -  Female subjects who are pregnant or nursing mothers

          -  Received an investigational drug in the past 90 days

          -  Unable to swallow large capsules</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>36</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>University of Adelaide - Adelaide</hospital>
    <hospital>Peninsular Specialist Centre - Kipparing</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Kipparing</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Avigen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety, tolerability and pharmacokinetics of
      AV411 after single and multiple doses in patients with chronic neuropathic pain due to
      diabetes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00576277</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>